Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of ...

Novavax swings to profit in Q4 CEO remains optimistic despite U.S. regulatory uncertainties Shares surge over 22% after strong results Feb 26 (Reuters) - Novavax (NVAX.O), opens new tab raised its ...

Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M ...

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, a move that piled onto fresh concerns from a Bank of America downgrade and ...